OPKO Acquires ModeX Therapeutics
OPKO Acquires ModeX Therapeutics
Our lead nephrology product, Rayaldee® (calcifediol), is approved by the U.S Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3-4 chronic kidney disease (CKD) with vitamin D insufficiency. A phase 2 clinical trial to evaluate the safety and efficacy of Rayaldee® to treat SHPT is currently underway in patients with stage 5 CKD who require regular hemodialysis.
Learn MoreSelective androgen receptor modulators (SARMs) are a class of androgen receptor ligands exhibiting modified anabolic and androgenic effects. We believe OPK88004 holds considerable promise for a variety of clinical indications, such as frailty and functional limitations associated with aging and chronic illnesses, cancer and osteoporosis.
Learn MoreSHPT (CKD stage 5)
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Market Phase not started
|
Phase 2 in progress (F: 1H 2020)
Hypophosphatemia (CKD Stage 5)
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Market Phase not started
|
Phase 3 Ready
Obesity and Diabetes
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Market Phase not started
|
Phase 2 Complete March 2019
Exploratory
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Phase 2
Hemophilia
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Market Phase not started
|
IV administration: Phase 2a completed
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Subcutaneous Administration: Phase 1 completed
Growth hormone deficiency
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Market Phase not started
|
Adults: Phase 3 complete
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Market Phase not started
|
Pediatrics: Phase 3 complete, OLE in progress
Dravet Syndrome
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Pre-clinical
Short Bowel Syndrome
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Pre-clinical
Acromegaly
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Pre-clinical
SPIGFD
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
---|---|---|---|---|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Pre-clinical